150 related articles for article (PubMed ID: 23448725)
1. Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research.
Lynch JA; Khoury MJ; Borzecki A; Cromwell J; Hayman LL; Ponte PR; Miller GA; Lathan CS
Genet Med; 2013 Aug; 15(8):630-8. PubMed ID: 23448725
[TBL] [Abstract][Full Text] [Related]
2. Implementation of the 21-gene recurrence score test in the United States in 2011.
Lynch JA; Berse B; Petkov V; Filipski K; Zhou Y; Khoury MJ; Hassett M; Freedman AN
Genet Med; 2016 Oct; 18(10):982-90. PubMed ID: 26890451
[TBL] [Abstract][Full Text] [Related]
3. EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer.
Hung A; Lee KM; Alba PR; Li Y; Gao AZ; Hintze BJ; Efimova OV; Shenolikar R; Pavilack M; Simmons D; Kelley MJ; Lynch JA; Reed SD
Cancer Treat Res Commun; 2021; 27():100327. PubMed ID: 33549984
[TBL] [Abstract][Full Text] [Related]
4. Clinical Use of Epidermal Growth Factor Receptor Testing in Patients With Advanced Lung Cancer by Physicians: Survey of US and International Patterns.
Peters M; Kim ES; Hirsch V
J Glob Oncol; 2019 Feb; 5():1-7. PubMed ID: 30811306
[TBL] [Abstract][Full Text] [Related]
5. Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.
Lynch JA; Berse B; Rabb M; Mosquin P; Chew R; West SL; Coomer N; Becker D; Kautter J
BMC Cancer; 2018 Mar; 18(1):306. PubMed ID: 29554880
[TBL] [Abstract][Full Text] [Related]
6. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.
Leighl NB; Rekhtman N; Biermann WA; Huang J; Mino-Kenudson M; Ramalingam SS; West H; Whitlock S; Somerfield MR
J Clin Oncol; 2014 Nov; 32(32):3673-9. PubMed ID: 25311215
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.
Hull LE; Lynch JA; Berse BB; DuVall SL; Chun DS; Venne VL; Efimova OV; Icardi MS; Kelley MJ
Clin Breast Cancer; 2018 Apr; 18(2):135-143. PubMed ID: 29306660
[TBL] [Abstract][Full Text] [Related]
8. [National variation in molecular diagnostics in metastatic lung cancer].
Kuijpers CCHJ; van den Heuvel MM; Overbeek LIH; van Slooten HJ; van Lindert ASR; Damhuis RAM; Willems SM
Ned Tijdschr Geneeskd; 2018 Dec; 162():. PubMed ID: 30570921
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
10. Cancer diagnostics: decision criteria for marker utilization in the clinic.
Taube SE; Jacobson JW; Lively TG
Am J Pharmacogenomics; 2005; 5(6):357-64. PubMed ID: 16336001
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Qi YT; Hou Y; Qi LC
Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
[TBL] [Abstract][Full Text] [Related]
12. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
[TBL] [Abstract][Full Text] [Related]
13. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
[TBL] [Abstract][Full Text] [Related]
14. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
15. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust.
Berg J; Fjellbirkeland L; Suhrke P; Jebsen P; Lund-Iversen M; Kleinberg L; Helgeland L; Brustugun OT; Helland Å
Acta Oncol; 2016; 55(2):149-55. PubMed ID: 26313507
[TBL] [Abstract][Full Text] [Related]
17. Lung adenocarcinoma: Assessment of epidermal growth factor receptor mutation status based on extended models of diffusion-weighted image.
Yuan M; Pu XH; Xu XQ; Zhang YD; Zhong Y; Li H; Wu JF; Yu TF
J Magn Reson Imaging; 2017 Jul; 46(1):281-289. PubMed ID: 28054731
[TBL] [Abstract][Full Text] [Related]
18. Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.
Kogo M; Fujimoto D; Hosoya K; Nagata K; Nakagawa A; Tachikawa R; Yamashita D; Kitamura Y; Imai Y; Tomii K
BMC Cancer; 2020 Feb; 20(1):104. PubMed ID: 32028905
[TBL] [Abstract][Full Text] [Related]
19. EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC.
Penzel R; Sers C; Chen Y; Lehmann-Mühlenhoff U; Merkelbach-Bruse S; Jung A; Kirchner T; Büttner R; Kreipe HH; Petersen I; Dietel M; Schirmacher P
Virchows Arch; 2011 Jan; 458(1):95-8. PubMed ID: 21057810
[TBL] [Abstract][Full Text] [Related]
20. Identification of epidermal growth factor receptor mutations in pulmonary adenocarcinoma using dual-energy spectral computed tomography.
Li M; Zhang L; Tang W; Jin YJ; Qi LL; Wu N
Eur Radiol; 2019 Jun; 29(6):2989-2997. PubMed ID: 30367185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
